Tagged with

China 2024 marks 30 years for Takeda in China, and the company has been outstripping the overall market to grow by double-digits in the country since 2020. Sean Shan discusses how he has led this remarkable trajectory, focusing on Takeda’s strategic vision, key product launches, and commitment to innovation. He highlights…

LatAm A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4 million investment in Brazil, and SteinCares’ plasma derivatives deal with Biotest.   Record dengue outbreak in Americas kills 7,700 this…

Saudi Arabia If the number of strategic deals and industry announcements coming out of the recent CPHI Middle East in Riyadh are anything to go by, Saudi Arabia’s ambition to become a regional and global innovation hub is becoming a reality. Read on for some highlights from the first regional edition of…

China Shawn Leung, CEO of Chinese biotech SinoMab, discusses the”Biotech 3.0″ philosophy that characterizes the company as it strives for both scientific innovation and differentiation. He highlights SinoMab’s atopic dermatitis and asthma candidate that aims to fill current treatment gaps and its rheumatoid arthritis therapy, which has already cleared two major…

Saudi Arabia Simona Grandits, VP of EEMEA at QIAGEN, reflects on the evolution of the German company whose revenues are now split between life sciences and molecular diagnostics, and the growing importance of bioinformatics for which QIAGEN is developing a data centre in Saudi Arabia. Grandits also reviews QIAGEN’s preventive healthcare initiatives…

India Shagun Sharma, Vipul Kumar Gupta, and Helene Sou of Takeda, writing in the December 2024 edition of DIA’s Global Forum magazine, look at how updates to India’s regulatory framework for pharmaceuticals are impacting the industry.   Since 2001, the regulatory environment for clinical research and drug development in India has…

Africa John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into Africa have yet to reach fruition.   Recent pandemics have triggered calls for deglobalization in the production of medical products…

Puerto Rico CytoImmune, founded in 2017 and established in Puerto Rico in 2020, is focused on developing immune-based therapies using proprietary natural killer (NK) cells. CEO Dr José Eduardo Vidal discusses the biotech’s innovative approach, the access promise of allogeneic NK cells as opposed to T-cell therapies, the advantages of setting up…

USA The Biosecure Act has been excluded from a recent key defense spending bill, leaving its future unclear. But whether or not it ends up being passed, the legislation has already proved detrimental for the targeted Chinese companies and the new Trump administration’s “America first” stance may have other adverse effects…

Japan A summary of some of the biggest stories coming out of Japan’s pharma industry, including Teva’s divestment of joint venture Teva-Takeda; GE HealthCare’s takeover of Nihon Medi-Physics; Takeda’s blood cancer anemia drug licensing deal with Keros, and Astellas’ new cell therapy research site in Japan.   Pharma firm Teva to…

Puerto Rico Juan Ignacio Diddi, GM of BMS Puerto Rico & Caribbean, has over 20 years of experience in the pharmaceutical industry, having held various roles across Latin America before taking on the role leading BMS Puerto Rico and the Caribbean in 2022. He focuses on ensuring early access to therapies, fostering…

China Dr Yingjia Zhang and Simon Hua of leading China-based CRO Biometas delve into the company’s rapid expansion in the preclinical space, strategic growth plans, and its positioning in the global CRO market. Focused on both organic growth and potential acquisitions, Biometas is leveraging a strong client base in the US…